Insuman Rapid (Insulin Human)

Insulin human binds to insulin receptors on cell surfaces, initiating a signaling cascade that activates phosphoinositide‑3‑kinase and downstream pathways. This leads to the translocation of GLUT‑4 transporters to the plasma membrane, enhancing glucose uptake in muscle and adipose tissue, promoting glycogen synthesis, and suppressing hepatic glucose production, thereby lowering circulating blood glucose.

The dose of Insuman Rapid is individualized by the prescribing healthcare professional based on the patient’s carbohydrate intake, blood‑glucose targets, and overall insulin regimen. Dosing may be administered before meals or as a correction dose, and adjustments are made according to self‑monitoring results and clinical response.

Insuman Rapid is classified as Pregnancy Category B, indicating that animal studies have not shown risk and there are no well‑controlled studies in pregnant women. It may be used when the potential benefit justifies the potential risk. Limited data are available for breastfeeding; the decision should be made by the clinician based on risk‑benefit assessment.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the required import documentation.

Insuman Rapid contains human insulin, whereas many alternatives use insulin analogues such as insulin lispro or aspart. Human insulin has a similar onset of action but may have a slightly longer duration compared with some analogues. Choice depends on clinical response, cost considerations, and individual patient factors, with human insulin often offering a cost‑effective option.

Insuman Rapid should be stored at 2‑8 °C (refrigerated) and protected from light. Do not freeze or shake the vial. Once in use, the product may be kept at room temperature (up to 30 °C) for a maximum of 28 days, after which any remaining solution should be discarded.

Insuman Rapid is administered by subcutaneous injection into the abdomen, thigh, or upper arm using a sterile needle. It is typically injected 0–15 minutes before a meal or as a correction dose for elevated glucose. Proper injection technique and rotation of sites help reduce local reactions and ensure consistent absorption.

The most serious risks include severe hypoglycemia, which can cause loss of consciousness or seizures, and rare systemic allergic reactions such as anaphylaxis. Patients should be educated to recognize early signs of hypoglycemia and to seek immediate medical attention if an allergic reaction occurs.

Insuman Rapid is contraindicated in individuals with a known hypersensitivity to human insulin or any excipients in the formulation. It should also be avoided in patients with severe hypoglycemia until the condition is corrected, and in those where insulin therapy is not indicated, such as certain cases of non‑diabetic hypoglycemia.